Respiratory Diseases

>

Latest News

Budesonide-Based Triple Therapy Most Effective vs Dual Therapy for COPD / image credit Breztri Aeorsphere package couretesy of AstraZeneca
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD

May 9th 2024

A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.

©Oleksandr/stock.adobe.com via AI
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD

May 8th 2024

Anxiety Raises Risk for Acute Exacerbations in Older Adults with COPD: Daily Dose / image credit: ©New Africa/AdobeStock
Anxiety Raises Risk for Acute Exacerbations in Older Adults with COPD: Daily Dose

May 8th 2024

Anxiety Linked to Increased Risk for Acute Exacerbations in Older Adults with COPD/image credit older woman sad: ©justlight/stock.adobe.com
Anxiety Linked to Increased Risk for Acute Exacerbations in Older Adults with COPD

May 2nd 2024

Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose / image credit: ©New Africa/AdobeStock
Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose

April 23rd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.